Contributed to PharmaLeaders by: Richard Zwickel, Chairman and CEO POCN Group Each year in the United States, about 264,000 cases of breast cancer are diagnosed in women and about 2,400 cases are diagnosed in men. Nearly 42,500 people die from the disease annually. Nurse practitioners (NPs) and physician associates (PAs) take an active role in breast […]
Featured Article
Switching to omnichannel in pharma: What are the challenges?
By Andrea
Article authored and contributed to PharmaLeaders by: Pavel Klymenko, Head of Omnichannel Hub at Viseven I’ve been in digital marketing for more than 15 years. From the beginning of my career, I witnessed the evolution of online communication in different markets. With the increasing number of messages sent by many companies via multiple platforms, customers got […]
White Papers

Engaging Users of Healthcare Provider Communities
Ninety-nine percent of all U.S. More about the punters page physicians use the Internet to gather clinical information. Sixty percent of healthcare … FREE Download

Whitepaper: Execute a 5-Step Framework for Data Compliance in Healthcare Marketing in the 2020s
The 2020s will transform how consumers and businesses interact with each other as vast amounts of personal and contextually relevant data will be … FREE Download
Industry News
AFT and Salus Pharmaceuticals sign agreement for pain treatment Maxigesic IV
Under the terms of the partnership deal between the companies, Hyloris will receive a share on any revenues related to product, such as royalties, license fees, milestone payments, The post AFT and Salus Pharmaceuticals sign agreement for pain treatment Maxigesic IV appeared first on Pharmaceutical … [Read More...]
GSK receives orphan drug designation for Benlysta to treat systemic sclerosis
Initially, the FDA approved Benlysta for the treatment of active systemic lupus erythematosus (SLE). GSK noted that it is the first and only approved biologic for SLE as The post GSK receives orphan drug designation for Benlysta to treat systemic sclerosis appeared first on Pharmaceutical Business … [Read More...]
TScan Therapeutics receives FDA clearance for IND applications
Serving as the primary IND for TScan’s solid tumour programme, T-Plex will enable customised combinations of T cell receptor (TCR)-engineered T cell therapies (TCR-T) to be given to The post TScan Therapeutics receives FDA clearance for IND applications appeared first on Pharmaceutical Business … [Read More...]
US FDA grants fast track designation to Artiva’s lead programme AB-101
AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use along with monoclonal antibodies or innate-cell engagers in the out-patient environment. Artiva The post US FDA grants fast track designation to Artiva’s lead … [Read More...]